US Asthma Guidelines Confirm Accolate's Place In Therapy

3 March 1997

Zeneca's leukotriene D4 receptor blocker Accolate (zafirlukast) is nowincluded in newly-issued guidelines for the management of patients with asthma in the USA.

Accolate is listed in the new guidelines as a therapy suitable for Step 2 asthma - or mild, persistent asthma - along with older preventive drugs. As expected, the guidelines place Accolate in a steroid-sparing role, targeting the underlying inflammation that characterizes the disorder in cases where more potent inhibition with steroids is not yet appropriate in the face of potential steroid-related side effects.

Since its launch in the USA in November 1996, Accolate has been prescribed for more than 130,000 patients. Its twice-daily, oral route of administration has made it a popular preventive medication for asthmatics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight